



# Atezolizumab

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.  
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

## General description

INN	Atezolizumab
ATC codes	L01XC18
Medicine type	Biological agent
EML status history	Application rejected in 2019 (TRS 1021) for <b>Other specified malignant neoplasms of bronchus or lung</b> Application rejected in 2023 (TRS 1049) for <b>Other specified malignant neoplasms of bronchus or lung</b>
Therapeutic equivalent for	pembrolizumab for Other specified malignant neoplasms of bronchus or lung
Wikipedia	<a href="#">Atezolizumab</a> 
DrugBank	<a href="#">Atezolizumab</a> 

## Recommendations

Section Immunomodulators

Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion

### Indications

Other specified malignant neoplasms of bronchus or lung

